일회용 복막투석 배액백 시장 : 세계 예측(2026-2032년)

The Disposable Peritoneal Dialysis Drainage Bag Market is projected to grow by USD 1,215.66 million at a CAGR of 8.14% by 2032.

Disposable Peritoneal Dialysis Drainage Bags: Executive Overview

Disposable peritoneal dialysis drainage bags are single-use components used to collect effluent during peritoneal dialysis. Their clinical value depends on secure connections, leak resistance, fluid visibility, compatibility with dialysis systems, and straightforward disposal. Demand conditions are shaped by the prevalence of kidney failure, the use of home-based dialysis, infection-prevention priorities, healthcare access, reimbursement practices, and the availability of trained support. Product evaluation therefore extends beyond the bag itself to include packaging integrity, handling workflow, traceability, and waste-management requirements.

Care Delivery and Sustainability Are Reshaping Product Requirements

The landscape is shifting toward home-centered care, simplified setup, and stronger infection-control routines. These changes favor drainage bags that are intuitive for patients and caregivers, minimize connection steps, support clear visual inspection, and reduce the likelihood of spillage during exchanges. Providers are also placing greater emphasis on reliable supply continuity, standardized fittings, and documentation that supports quality management. At the same time, single-use plastics are receiving closer environmental scrutiny, increasing interest in material efficiency, responsible packaging, and disposal practices that remain consistent with clinical safety.

Artificial Intelligence Improves Planning, Quality Control, and Patient Support

Artificial intelligence can influence this market indirectly through better dialysis pathway management rather than by replacing the drainage bag. Predictive tools may help identify patients at risk of complications, support exchange scheduling, and improve inventory planning for home-care programs. Computer vision and automated inspection can assist manufacturers with detecting seal, printing, or packaging defects. Digital systems may also help flag unusual drainage patterns for clinical review, although implementation requires validated data, cybersecurity safeguards, human oversight, and compliance with medical-device and privacy requirements. AI should therefore be treated as an enabling layer around a clinically validated disposable product.

Regional Insights: Access, Home Therapy, and Regulation Define Adoption Conditions

North America is characterized by established dialysis infrastructure, expanding interest in home therapies, and close attention to reimbursement, product standardization, and infection prevention. Europe combines mature clinical systems with strong device oversight and growing environmental expectations, making usability, conformity, and waste handling important considerations. Asia-Pacific presents varied conditions, including large patient populations, expanding healthcare capacity, and differing levels of access to home dialysis and consumables. Latin America is influenced by uneven reimbursement, import dependence in some markets, and efforts to broaden renal-care access. The Middle East shows differentiated adoption linked to public and private healthcare investment, while Africa remains strongly affected by affordability, supply continuity, infrastructure, and availability of trained personnel. Across all regions, local registration, distribution reliability, and practical support for patients and caregivers are central to sustained use.

Group Insights: Economic and Political Blocs Create Diverse Operating Environments

Within ASEAN, differences in healthcare financing, regulatory maturity, and urban-rural access make adaptable distribution and training models important. BRICS markets combine substantial healthcare needs with varied manufacturing capabilities, reimbursement structures, and procurement systems, requiring country-specific execution rather than a single regional approach. The European Union emphasizes harmonized device requirements, patient safety, documentation, and sustainability considerations. G7 markets generally place strong weight on clinical evidence, quality systems, supply resilience, and home-care usability. GCC countries often benefit from concentrated healthcare investment and centralized procurement opportunities, while workforce capacity and care-model design remain relevant. NATO members span diverse health systems, but many share heightened attention to critical medical-supply resilience and continuity planning.

Country Insights: Local Regulation and Care Models Drive Market Differences

Australia combines strong clinical governance with geographically dispersed care needs, supporting interest in dependable home-care logistics. Brazil's large and varied health system makes affordability, public procurement, and regional distribution important. Canada's geography and provincial healthcare structures elevate supply reliability and remote patient support. China is shaped by expanding healthcare capacity, domestic production priorities, and regulatory requirements. France, Germany, Italy, and Spain operate within a structured European framework while differing in procurement and care-delivery practices. India's diversity in access, affordability, and clinical infrastructure favors scalable solutions and practical training. Japan places emphasis on quality, reliability, and an aging-care context, while South Korea combines advanced healthcare capabilities with rigorous product expectations. Mexico's adoption conditions reflect public-private system variation and logistics across regions. Russia is influenced by domestic supply considerations, regulatory conditions, and healthcare access differences. The United Kingdom emphasizes clinically governed procurement, home-dialysis pathways, and post-market oversight. The United States is shaped by home-care adoption, reimbursement rules, supplier continuity, and detailed quality and regulatory expectations.

Actions for Leaders: Build Trust Through Usability, Resilience, and Evidence

Industry leaders should prioritize designs that reduce handling complexity, prevent leakage, and make fluid assessment straightforward for patients and caregivers. They should validate interoperability across relevant dialysis systems, strengthen packaging and lot traceability, and maintain documented controls for sterility or cleanliness claims as applicable. Supply strategies should include qualified sources, regional contingency planning, and demand visibility from home-care providers. Evidence programs should measure not only device performance but also user errors, waste handling, training burden, and patient experience. Manufacturers and providers should also assess material reduction and disposal options without compromising infection control. Finally, responsible use of digital and AI tools requires clinical validation, transparent governance, cybersecurity controls, and clear escalation to healthcare professionals.

Methodology: Evidence-Based Assessment of Product and Care-System Drivers

This executive summary uses the defined product category and the specified regional, group, and country coverage as the analytical scope. The assessment considers publicly documented clinical practices, healthcare delivery patterns, medical-device regulatory principles, infection-prevention requirements, home-dialysis workflows, procurement considerations, and sustainability pressures. Insights are synthesized qualitatively across product design, patient and caregiver usability, manufacturing quality, distribution, reimbursement, infrastructure, and policy conditions. No market estimates, market shares, forecasts, or company-specific claims are used. Regional and country observations are framed as contextual drivers and should be validated against current local regulations, procurement rules, and clinical guidance before operational decisions are made.

Conclusion: Reliable Single-Use Drainage Supports Safer, More Flexible Dialysis

The disposable peritoneal dialysis drainage bag market is closely connected to the broader evolution of renal care toward safer, more manageable, and increasingly home-based treatment. Competitive relevance depends on dependable performance, intuitive handling, compatibility, regulatory discipline, and resilient supply-not on the bag alone. Regional differences in access, financing, infrastructure, and oversight require localized strategies, while AI and digital tools can improve surrounding planning and quality processes when governed responsibly. Leaders that combine patient-centered design with evidence, operational reliability, and credible sustainability practices will be better positioned to support clinicians, caregivers, and patients across diverse healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Disposable Peritoneal Dialysis Drainage Bag Market, by Product Type

• 7.1. Introduction
• 7.2. Multi-Chamber Bag
  • 7.2.1. Five-Chamber
  • 7.2.2. Four-Chamber
• 7.3. Three-Chamber Bag
• 7.4. Two-Chamber Bag

8. Disposable Peritoneal Dialysis Drainage Bag Market, by Technology

• 8.1. Introduction
• 8.2. Closed System
  • 8.2.1. Automated Peritoneal Dialysis
  • 8.2.2. Continuous Ambulatory Peritoneal Dialysis
• 8.3. Open System

9. Disposable Peritoneal Dialysis Drainage Bag Market, by Bag Capacity

• 9.1. Introduction
• 9.2. Greater Than Three Thousand Milliliter
• 9.3. One Thousand Milliliter
• 9.4. Three Thousand Milliliter
• 9.5. Two Thousand Milliliter

10. Disposable Peritoneal Dialysis Drainage Bag Market, by Material Type

• 10.1. Introduction
• 10.2. Polyethylene
• 10.3. Polyvinyl Chloride
• 10.4. Thermoplastic Elastomer

11. Disposable Peritoneal Dialysis Drainage Bag Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Center
• 11.3. Clinic
• 11.4. Home Care Settings
  • 11.4.1. Assisted Care
  • 11.4.2. Self Care
• 11.5. Hospital

12. Disposable Peritoneal Dialysis Drainage Bag Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Disposable Peritoneal Dialysis Drainage Bag Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Disposable Peritoneal Dialysis Drainage Bag Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Angiplast Private Limited
• 16.2. Asahi Kasei Corporation
• 16.3. B. Braun Melsungen AG
• 16.4. Baxter International Inc.
• 16.5. Benaka Health Care
• 16.6. Bioteque Corporation
• 16.7. Boen Healthcare Co., Ltd.
• 16.8. Changzhou Holinx Industries Co., Ltd.
• 16.9. China Resources Double-Crane Pharmaceutical Co., Ltd.
• 16.10. Dongyang Medical Co., Ltd.
• 16.11. Fresenius Medical Care AG & Co. KGaA
• 16.12. Jiangsu Jianyu Medical Co., Ltd.
• 16.13. Jiangsu Yangtze River Medical Technology Co., Ltd.
• 16.14. JMS Co., Ltd.
• 16.15. Medline Industries, LP
• 16.16. Mitra Industries
• 16.17. Nipro Corporation
• 16.18. Poly Medicure Limited
• 16.19. Qingdao Huaren Medical Supplies Co., Ltd.
• 16.20. Terumo Corporation

17. Key Experts